A latex composition containing a conjugated diene polymer latex and a medium-chain fatty acid glyceride, wherein a content proportion of the medium-chain fatty acid glyceride is 1 to 40 parts by weight with respect to 100 parts by weight of the conjugated diene polymer. In the present invention, a medium-chain fatty acid forming the medium-chain fatty acid glyceride is preferably a fatty acid having 6 to 18 carbon atoms. In the present invention, the medium-chain fatty acid glyceride is preferably a medium-chain fatty acid triglyceride. The latex composition preferably further contains a crosslinking agent.

A latex composition is formed by adding an aqueous solution of an aluminum compound to a latex of a carboxyl group-containing synthetic polyisoprene and/or a carboxyl group-containing styrene-isoprene-styrene block copolymer. In the latex composition, the aqueous solution of an aluminum compound preferably has a pH of 5 to 13. In the latex composition, the aqueous solution of an aluminum compound is preferably an aqueous solution of a metal salt of aluminate.

A latex composition is formed by adding an aqueous solution of an aluminum compound to a latex of a carboxyl group-containing synthetic polyisoprene and/or a carboxyl group-containing styrene-isoprene-styrene block copolymer. In the latex composition, the aqueous solution of an aluminum compound preferably has a pH of 5 to 13. In the latex composition, the aqueous solution of an aluminum compound is preferably an aqueous solution of a metal salt of aluminate.

A method for producing a synthetic polyisoprene latex, including a step of mixing a latex of synthetic polyisoprene (A) synthesized by use of a Ziegler type catalyst and a latex of synthetic polyisoprene (B) synthesized by use of an organic alkali metal catalyst at a weight ratio of “synthetic polyisoprene (A): synthetic polyisoprene (B)=10:90 to 90:10”. In the method, preferably, the weight average molecular weight of the synthetic polyisoprene (A) is 100,000 to 3,000,000 and the weight average molecular weight of the synthetic polyisoprene (B) is 1,000,000 to 5,000,000.

Provided is a dip molding composition including, at least: an elastomer that contains a (meth)acrylonitrile-derived structural unit, an unsaturated carboxylic acid-derived structural unit, and a butadiene-derived structural unit in a polymer main chain; an epoxy crosslinking agent; water; and a pH modifier, in which dip molding composition the elastomer contains the (meth)acrylonitrile-derived structural unit in an amount of 20 to 40% by weight, the unsaturated carboxylic acid-derived structural unit in an amount of 1 to 10% by weight, and the butadiene-derived structural unit in an amount of 50 to 75% by weight, and the epoxy crosslinking agent includes an epoxy crosslinking agent containing an epoxy compound having three or more epoxy groups in one molecule and has a dissolution rate in water of 10 to 70% as determined by a specific measurement method.

Provided is a dip molding composition including, at least: an elastomer that contains a (meth)acrylonitrile-derived structural unit, an unsaturated carboxylic acid-derived structural unit, and a butadiene-derived structural unit in a polymer main chain; an epoxy crosslinking agent; water; and a pH modifier, in which dip molding composition the elastomer contains the (meth)acrylonitrile-derived structural unit in an amount of 20 to 40% by weight, the unsaturated carboxylic acid-derived structural unit in an amount of 1 to 10% by weight, and the butadiene-derived structural unit in an amount of 50 to 75% by weight, and the epoxy crosslinking agent includes an epoxy crosslinking agent containing an epoxy compound having three or more epoxy groups in one molecule and has a dissolution rate in water of 10 to 70% as determined by a specific measurement method.

Resorbable implants, coverings and receptacles comprising poly(butylene succinate) and copolymers thereof have been developed. The implants are preferably sterilized, and contain less than 20 endotoxin units per device as determined by the limulus amebocyte lysate (LAL) assay, and are particularly suitable for use in procedures where prolonged strength retention is necessary, and can include one or more bioactive agents. The implants may be made from fibers and meshes of poly(butylene succinate) and copolymers thereof, or by 3d printing molding, pultrusion or other melt or solvent processing method. The implants, or the fibers preset therein, may be oriented. These coverings and receptacles may be used to hold, or partially/fully cover, devices such as pacemakers and neurostimulators. The coverings, receptacles and implants described herein, may be made from meshes, webs, lattices, non-wovens, films, fibers, foams, molded, pultruded, machined and 3D printed forms.

Resorbable implants, coverings and receptacles comprising poly(butylene succinate) and copolymers thereof have been developed. The implants are preferably sterilized, and contain less than 20 endotoxin units per device as determined by the limulus amebocyte lysate (LAL) assay, and are particularly suitable for use in procedures where prolonged strength retention is necessary, and can include one or more bioactive agents. The implants may be made from fibers and meshes of poly(butylene succinate) and copolymers thereof, or by 3d printing molding, pultrusion or other melt or solvent processing method. The implants, or the fibers preset therein, may be oriented. These coverings and receptacles may be used to hold, or partially/fully cover, devices such as pacemakers and neurostimulators. The coverings, receptacles and implants described herein, may be made from meshes, webs, lattices, non-wovens, films, fibers, foams, molded, pultruded, machined and 3D printed forms.

The present application relates to an elastomeric article, such as a glove, comprising: (i) an elastomeric film comprising one or more film layers, and including an external surface and an internal surface, (ii) an antimicrobial agent that is effective against both beneficial and harmful microorganisms on the external surface of the elastomeric film, and (iii) a skin-protective agent selected from a probiotic, a prebiotic, or a combination thereof on the internal surface of the elastomeric film; wherein the inner surface of the film is free of an antimicrobially-effective amount of an antimicrobial agent that is effective against both beneficial and harmful microorganisms. The elastomeric articles may further comprise a barrier film layer that provides separation between the antimicrobial agent and the skin-protective agent. Also described are methods for the manufacture of such articles.

The present application relates to an elastomeric article, such as a glove, comprising: (i) an elastomeric film comprising one or more film layers, and including an external surface and an internal surface, (ii) an antimicrobial agent that is effective against both beneficial and harmful microorganisms on the external surface of the elastomeric film, and (iii) a skin-protective agent selected from a probiotic, a prebiotic, or a combination thereof on the internal surface of the elastomeric film; wherein the inner surface of the film is free of an antimicrobially-effective amount of an antimicrobial agent that is effective against both beneficial and harmful microorganisms. The elastomeric articles may further comprise a barrier film layer that provides separation between the antimicrobial agent and the skin-protective agent. Also described are methods for the manufacture of such articles.